Department of Medical Oncology, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, Maharashtra, India.
Department of Medical Oncology, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, Maharashtra, India
BMJ Open. 2021 Jun 29;11(6):e047376. doi: 10.1136/bmjopen-2020-047376.
IMPORTANCE: The Cancer Aging Research Group (CARG) toxicity score is used to assess toxicity risk in geriatric patients receiving chemotherapy. OBJECTIVE: The primary aim was to validate the CARG score in geriatric patients treated with curative intent chemotherapy in predicting grade 3-5 toxicities. DESIGN: This was a longitudinal prospective observational study. SETTING: Tata Memorial Hospital, Mumbai, India, a tertiary cancer care referral centre. PARTICIPANTS: Patients, aged ≥65 years, with gastrointestinal, breast or gynaecological stage I-III cancers being planned for curative intent chemotherapy. A total of 270 patients were required for accrual in the study. EXPOSURES: Total risk score ranged from 0 (lowest toxicity risk) to 19 (highest toxicity risk). MAIN OUTCOMES AND MEASURES: The primary endpoint of the study was to evaluate whether the CARG risk score predicted for grade 3-5 toxicities. RESULTS: The study cohort of 270 patients had a mean age of 69 (65-83) years, with the most common cancers being gastrointestinal (79%). Fifty-two per cent of patients had atleast one grade 3-5 toxicity. The risk of toxicity was increased with an increasing risk score (42% low risk, 51% medium risk and 79% high risk; p<0.001). There was no association between either Eastern Cooperative Oncology Group (ECOG) performance status (p=0.69) or age-adjusted Charlson Comorbidity Index (p=0.79) risk categories and grade 3-5 chemotherapy toxicities. CONCLUSIONS AND RELEVANCE: This study validates the CARG risk score in predicting for grade 3-5 toxicities in geriatric oncology patients receiving curative intent chemotherapy and can be considered as the standard of care before planning chemotherapy in every elderly patient. TRIAL REGISTRATION NUMBER: CTRI/2016/10/007357; Results.
重要性:癌症衰老研究组(CARG)毒性评分用于评估接受化疗的老年患者的毒性风险。 目的:主要目的是验证 CARG 评分在接受根治性化疗的老年患者中预测 3-5 级毒性的能力。 设计:这是一项纵向前瞻性观察性研究。 地点:印度孟买的塔塔纪念医院,这是一家三级癌症治疗转诊中心。 参与者:年龄≥65 岁、患有胃肠道、乳腺或妇科 I-III 期癌症、计划接受根治性化疗的患者。该研究需要招募 270 名患者。 暴露因素:总风险评分范围为 0(最低毒性风险)至 19(最高毒性风险)。 主要结果和测量:研究的主要终点是评估 CARG 风险评分是否预测 3-5 级毒性。 结果:该研究队列的 270 名患者平均年龄为 69(65-83)岁,最常见的癌症是胃肠道(79%)。52%的患者至少有 1 种 3-5 级毒性。随着风险评分的增加,毒性风险增加(低风险 42%,中风险 51%,高风险 79%;p<0.001)。ECOG 表现状态(p=0.69)或年龄调整后的 Charlson 合并症指数(p=0.79)风险类别与 3-5 级化疗毒性之间均无关联。 结论和相关性:本研究验证了 CARG 风险评分在预测接受根治性化疗的老年肿瘤患者 3-5 级毒性方面的有效性,并且可以在为每位老年患者计划化疗之前被视为标准护理。 试验注册编号:CTRI/2016/10/007357;结果。
ESMO Open. 2024-11
Curr Oncol Rep. 2024-1
Ecancermedicalscience. 2023-8-31
ESMO Open. 2016-4-12
J Clin Oncol. 2016-7-10
J Geriatr Oncol. 2013-6-14